Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 811 to 825 of 1364 results for social care

  1. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  2. Care pathway:- In the UK, what is the optimal care pathway for young people and adults with coexisting severe mental illness and substance misuse?

    Recommendation ID NG58/5 Question Care pathway:- In the UK, what is the optimal care pathway for young people and adults...

  3. Birch bark extract for treating epidermolysis bullosa (HST28)

    Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.

  4. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

  5. Carers:- In what context is it cost effective to increase uptake of flu vaccination among carers?

    This key target group can be difficult to identify, and people who provide care may not always identify themselves as carers. The...

  6. Dementia care:- How effective and cost effective is intermediate care including reablement for supporting people living with dementia?

    Recommendation ID NG74/4 Question Dementia care:- How effective and cost effective is intermediate care including...

  7. Assessment in non-specialist settings: What are the most effective approaches to assessment in non-specialist settings?

    research, see the rationale section on assessment and care by healthcare professionals and social care practitioners. Full...

  8. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

  9. Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

    Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.

  10. Dupilumab for treating moderate to severe atopic dermatitis (TA534)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.

  11. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  12. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  13. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.